CSL Limited to finalise Vifor Pharma acquisition and appointment of General Manager

CSL Limited (ASX: CSL) announced that it had received all necessary regulatory clearances for the purchase of Vifor Pharma AG, and the acquisition will be completed by 09 August 2022. The company expects that it will hold over 97% of Vifor shares after the completion of the acquisition. According to the Swiss takeover rules, the company will then proceed with the cancellation of the rest of the publicly held Vifor shares.

CSL Limited has also announced the appointment of Mr. Hervé Gisserot as a general manager to lead the Vifor business after the completion of the acquisition. Mr. Gisserot has more than 13 years of experience and is currently working as Chief Commercial Officer for Vifor Pharma.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au